Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

AVIR / Aviragen Therapeutics, Inc. EX-99.1

13h sec.gov
EX-99.1 Exhibit 99.1   Feb 14, 2018 Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen Therapeutics, Inc. (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-16.1

13h sec.gov
EX-16.1 Exhibit 16.1           Ernst & Young LLP Suite 1000 55 Ivan Allen Jr. Boulevard Atlanta, GA 30308         Tel: +1 404 874 8300 Fax: +1 404 817 5589 February 20, 2018 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated February 20, 2018, of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.) and are in agreement with the statements contained in the second and fifth paragraph on page one therein. (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-10.3

13h sec.gov
EX-10.3 Exhibit 10.3   INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of [•], 2018, between VAXART, INC., a Delaware corporation (the “Company”), and [•] (“Indemnitee”). RECITALS A. Highly competent persons have become more reluctant to serve corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against t (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-10.2

13h sec.gov
EX-10.2 Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM S (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-10.1

13h sec.gov
EX-10.1 Exhibit 10.1 Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of February 13, 2018 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Sched (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-3.2

13h sec.gov
EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF VAXART, INC. Vaxart, Inc. (f/k/a Aviragen Therapeutics, Inc.), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: The name of Corporation is Vaxart, Inc. SECOND: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of D (34-0)

AVIR / Aviragen Therapeutics, Inc. EX-3.1

13h sec.gov
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF AVIRAGEN THERAPEUTICS, INC. Aviragen Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY THAT: FIRST: That, upon action by unanimous written consent in lieu of a meeting of the Board of Directors of the Corporation (the “Board”) on December 27, 2017, the following resolutions were duly ado (34-0)

AVIR / Aviragen Therapeutics, Inc. FORM 8-K (Current Report)

13h sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2018     VAXART, INC. (Exact name of registrant as specified in its charter)       Delaware   001-35285   59-1212264 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No. (34-0)

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D., John M. Harland, and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D., John M. Harland, and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D., John M. Harland, and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D., John M. Harland, and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D. and Josh Seidenfeld, signing individually the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Wouter W. Latour, M.D. and Josh Seidenfeld, signing individually the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.

AVIR / Aviragen Therapeutics, Inc. POA DOCUMENT

2018-02-15 sec.gov
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of John M. Harland and Josh Seidenfeld, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Vaxart, Inc.


AVIR : Aviragen Therapeutics Stock Analysis and Research Report

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections. The company also have a preclinical RSV non-fusion inhibitor program.

In April 2017, the company engaged Stifel, Nicolaus and Company, Incorporated (“Stifel”) as its advisor to assist with the exploration of strategic alternatives (the “Strategic Review”). Stifel is providing a range of advisory services aimed to enhance stockholder value. The alternatives to be considered may include, but are not l...

Click for full article
CUSIP: 090694100